A Phase 4 interventional study of Extended-Release Buprenorphine (XRB) and Sublingual Buprenorphine (SLB) in Opioid Use Disorder, sponsored by NYU Langone Health. Recruiting at 4 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing sublocade in Opioid-Related Disorders — 2 open to participants now, 2 under way, none of them phase 3. Sublocade · Opioid-Related Disorders.
Among the 12 studies testing sublocade in Opioid-Related Disorders, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 4, and was the 10th registered.
1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.
Browse Opioid-Related Disorders studies →2 of the 12 studies testing sublocade in Opioid-Related Disorders are open now, in 1 country. Recruiting first, the newest first:
Lifespan · Sites in United States
Ages 18+
By country, each count listing its studies:
Sublocade: first FDA approval 2017 (SUBLOCADE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.
This study: male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 4 · Phase 4 5
First in 2019; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.
Median enrollment 21 across the 12 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 12 have an industry lead sponsor. The 9 most frequent:
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
23 studies in Opioid-Related Disorders by NYU Langone Health: 4 open now, 5 under way, 1 of them phase 3. Of 16 finished, 9 (56%) have results posted.
Among the 23 studies in Opioid-Related Disorders by NYU Langone Health, this one is the 15th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 4, and was the 22nd registered.
NYU Langone Health’s Opioid-Related Disorders studies by the year they started, since 2010.
2 of the studies testing sublocade in Opioid-Related Disorders that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06051890NYU Langone HealthAssessing Optimal XRB Initiation Points in Jail | 2026-12-01 |
| NCT06880718LifespanInjectable Buprenorphine in Prison: A Preference Trial | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing sublocade in Opioid-Related Disorders, from their registry updates:
Among NYU Langone Health’s 23 in Opioid-Related Disorders:
This tab as a report to print or save as PDF → With an account.
This application describes a 3-year, randomized controlled trial. Eligible, consenting adults (N=200) with existing sublingual buprenorphine (SLB) prescriptions who enter Middlesex County House of Corrections (MCHOC) as pre-trial detainees will be randomized at admission on a 1:1 basis to be inducted onto extended-release buprenorphine (XRB) at the time of admission (experimental condition) or remain in SLB (E-TAU; all participants will also receive naloxone). The two approaches will be compared with regard to (1) the percentage of participants released from jail with at least 7 days of buprenorphine in their system, (2) percentage of participants continuing MOUD treatment in the community, and (3) infractions related to buprenorphine diversion.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to transition to treatment with XRB.
Drug: Extended-Release Buprenorphine (XRB)
Participants randomized to remain on-treatment with SLB.
Drug: Sublingual Buprenorphine (SLB)
XRB (Sublocade) will be delivered as a pre-filled 2cc subcutaneous monthly injection, using a 300mg starting dose in most cases (100mg starting doses are available per the study team's clinical judgement). XRB consists of a depot injectable formulation in polymeric solution to the abdomen and releases buprenorphine over 28-days (4-weeks) by diffusion as the polymer biodegrades. Prior to an initial injection, the participant must be stable for several days or longer on sublingual buprenorphine (SLB) at doses of 8mg/day or higher. Participants will receive at least one XRB monthly injection prior to release, which investigators anticipate to usually be the 300mg dose. Some participants will be recruited earlier during the incarceration (or experience delayed release dates and then longer than anticipated incarcerations); XRB will be continued monthly from the time of induction to the day of release.
Also known as: Sublocade
Maintenance of existing SLB prescription (treatment as usual).
Percentage of participants released from jail with at least 7 days of buprenorphine in their system
The percentage of participants leaving jail with at least 7 days of buprenorphine protection in their system. Measured using clinical and jail records.
Time frame: Up to Month 6
Percentage of participants continuing MOUD treatment in the community
Percentage of participants who continue to access medication for opioid use disorder (MOUD) once released from jail. This will be based on community clinic records indicating admission and retention.
Time frame: Up to Month 9
Plan to share: Yes — All of the de-identified individual participant data collected during the trial will be shared upon reasonable request beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research provided the investigator who proposes to use the data executes a data use agreement with NYU Langone Health. Requests may be directed to: david.farabee@nyulangone.org. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.
Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to david.farabee@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.
Of 48 non-industry phase 4 interventional studies under Opioid-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 55. This study's planned 17 months is below that.
Counting every sponsor, half of 52 studies reached it within 32 months; a quarter within 20 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sublocade